Abstract
Neuroblastoma (NB) is a kind of childhood cancer that is a prevailing and deadly solid neoplasm among pediatric malignancies. The transcriptional output of MIR938 is capable of participating in the posttranscriptional modulation of gene expression, whereby it exerts its regulatory effect by modulating both the stability and translation of target mRNAs. Previous studies showed that MIR938 was associated with many cancers. Hence, functional genetic variants in the MIR938 can be attributed to NB risk. We recruited 402 neuroblastoma patients and 473 controls from the Children’s Hospital of Nanjing Medical University and genotyped one MIR938 single-nucleotide polymorphism (SNP) (rs2505901 T>C). There were significant associations between the rs2505901 T>C and NB risk [CC vs. TT: adjusted odds ratio (OR) = 1.90, 95% confidence interval (CI) = 1.02–3.55, P=0.045; CC vs. TT/TC: adjusted OR = 2.02, 95% CI = 1.09–3.75, P=0.026]. This analysis of genotypes revealed that T>C increased the risk of NB. Some borderline significant different relationships were observed in the stratified analyses: age ≤ 18 months (adjusted OR = 2.95, 95% CI = 0.92–9.51, P=0.070), male sex (adjusted OR = 2.19, 95% CI = 0.95–5.08, P=0.067), and clinical stage III+IV (adjusted OR = 2.12, 95% CI = 0.98–4.56, P=0.055). The present study revealed that the MIR938 rs2505901 T>C polymorphism may be a potential risk factor for neuroblastoma in Chinese children. In the long term, conducting large and diverse sample studies from different ethnicities will indeed be crucial in determining the role of MIR938 polymorphisms in NB risk. By including individuals from various ethnic backgrounds, researchers can account for potential genetic variations that may exist between populations.
Keywords: MIR938, neuroblastoma, polymorphism, susceptibility
Introduction
Neuroblastoma (NB), an affliction that is a prevailing and deadly solid neoplasm among pediatric malignancies [1], accounts for approximately 7% of childhood cancer cases [2]. With a heterogeneous clinical range from localized or spontaneously regressing to widely metastatic disease [3], NB is strongly linked to pediatric malignancy mortality, especially in high-risk patients experiencing chemoresistant relapse, whose mortality rate is almost as high as 60% [2,4,5].
A previous study showed that NB might be associated with a few nongenetic factors, such as recreational drug use, marijuana use, hair dye use and prenatal exposure during pregnancy, but the nongenetic factor effect was very weak [6–8]. Compared with nongenetic factors, genetic factors play an important role in NB. NB cells often suffer from extensive, nonrandom genetic damage at multiple genetic loci. NB shows striking genetic heterogeneity characterized by various chromosomal/gene modifications and dysregulated expression of pivotal oncogenes that instigate tumor initiation and facilitate the advancement of the disease [1,9]. Segmental chromosome alterations such as 1p, 11q, and 14q deletions and 17q gain [5,10] and several gene alterations such as MYCN amplification [4,11,12], germline or somatic mutations of ALK [13–16] and PHOX2B [17,18], and rearrangements at ATRX [19] and at TERT [20] were common in NB cases, and these alterations also led to worse prognosis.
MicroRNAs (miRNAs) are a cohort of small (20–24 nucleotides) noncoding RNAs that orchestrate the posttranscriptional regulation of gene expression in multicellular organisms. Their impact is exerted through the modulation of mRNA stability and translation. Previous studies have shown that miRNA dysregulation is causal in many cases of cancer [21]. Moreover, miRNAs profiles can be surprisingly informative, revealing the developmental lineage and differentiation state of tumors [22]. MIR938 participates in the expression of miRNAs. Current existing articles have shown that MIR938 polymorphisms are associated with many kinds of diseases, including intestinal-type gastric cancer (intestinal-type GC) [23], colorectal cancer (CRC) [24], primary ovarian insufficiency [25], and idiopathic recurrent pregnancy loss [26].
Genome-wide association studies (GWASs) have provided evidence that common genetic variants are associated with neuroblastoma susceptibility. However, until now, no studies have revealed the relationship between MIR938 polymorphism and neuroblastoma. Incorporating multiple testing correction in the GWAS analysis may inadvertently lead to overlooking certain potential single-nucleotide polymorphisms (SNPs) with moderate risk effects [27]. Additional gene polymorphisms need to be identified.
Materials and methods
Study subjects
We randomly selected 402 children with neuroblastoma and 473 children without NB from the Children’s Hospital of Nanjing Medical University (Supplementary Table S1). Neuroblastoma cases were defined by biopsy and histology and stratified by the International Neuroblastoma Staging System (INSS) [28], and children without cancer were matched by similar population characteristics. All the participants’ parents or guardians signed informed consent forms, and clinical information was collected through personal interviews [29]. This study was approved by the Children’s Hospital of Nanjing Medical University institutional review board (Approval No: 202112141-1).
SNP selection and genotyping
The rs2505901 T>C polymorphism was chosen from our previous studies [30,31]. In addition, pertinent details regarding this selection are also available for reference. A TIANamp Blood DNA Kit was used to extract genomic DNA from peripheral blood donated by subjects. The selected MIR938 rs12416605 polymorphism was genotyped using a standard TaqMan real-time PCR method. The primers and probes sequences manufacturer is ThermoFisher Scientific and their ID is C__16253955_10.
Statistical analysis
We adopted the goodness-of-fit χ2 test to calculate Hardy–Weinberg equilibrium (HWE) in controls, the two-sided chi-square test to measure the difference in categorical variables between cases and controls and the t-test to measure the significance of continuous variables. Logistic regression analysis was used to test the association between candidate SNP and NB susceptibility, followed by further stratified analyses by age, sex, tumor sites, and clinical stages. All of these analyses were performed with SAS 9.4 (SAS Institute Inc., Cary, North Carolina).
Results
Association analysis of the rs2505901 T>C polymorphism with NB risk
There were 400 cases and 473 controls successfully genotyped. Complete information regarding the demographic profiles of all participants can be found in Supplementary Table S1, as well as in our previously published articles [29]. As shown in Table 1, the rs2505901 T>C was in accordance with HWE (HWE = 0.515). In our adjusted model, we observed a significant association between the MIR938 rs2505901 T>C polymorphism and an increased risk to neuroblastoma [CC vs. TT: adjusted odds ratio (OR) = 1.90, 95% confidence interval (CI) = 1.02–3.55, P=0.044; TT/TC vs. CC: adjusted OR = 2.02, 95% CI=1.09–3.75, P=0.026].
Table 1. MIR938 rs2505901 T>C polymorphism and neuroblastoma risk in children from Jiangsu province.
| Genotype | Cases (N=400) | Controls (N=473) | P* | Crude OR (95% CI) | P | Adjusted OR (95% CI)† | P † |
|---|---|---|---|---|---|---|---|
| rs2505901 (HWE = 0.515) | |||||||
| TT | 259 (64.75) | 299 (63.21) | 1.00 | 1.00 | |||
| TC | 113 (28.25) | 157 (33.19) | 0.83 (0.62–1.11) | 0.217 | 0.83 (0.62–1.11) | 0.213 | |
| CC | 28 (7.00) | 17 (3.59) | 1.90 (1.02–3.55) | 0.044 | 1.90 (1.02–3.55) | 0.045 | |
| Additive | 0.640 | 1.06 (0.84–1.32) | 0.639 | 1.06 (0.84–1.32) | 0.646 | ||
| Dominant | 141 (35.25) | 174 (36.79) | 0.638 | 0.94 (0.71–1.24) | 0.638 | 0.93 (0.71–1.23) | 0.629 |
| TT/TC | 372 (93.00) | 456 (96.41) | 1.00 | 1.00 | |||
| CC | 28 (7.00) | 17 (3.59) | 0.023 | 2.02 (1.09–3.75) | 0.026 | 2.02 (1.09–3.75) | 0.026 |
| T | 631 (78.88) | 755 (79.81) | 1.00 | 1.00 | |||
| C | 169 (21.13) | 191 (20.19) | 0.631 | 1.06 (0.84–1.34) | 0.630 | 1.06 (0.84–1.34) | 0.638 |
CI, confidence interval; HWE, Hardy–Weinberg equilibrium; OR, odds ratio.
χ2 test for genotype distributions between neuroblastoma cases and cancer-free controls.
Adjusted for age and sex.
Stratification analysis
Furthermore, we performed additional analyses by stratifying the data according to age, sex, site of origin, and clinical stage (Table 2) to investigate the relationship between the MIR938 rs2505901 T>C polymorphism and susceptibility to neuroblastoma.
Table 2. Stratified analysis for the association between MIR938 rs2505901 T>C polymorphism and neuroblastoma susceptibility.
| Variable | rs2505901 (cases/controls) | OR (95% CI) | P | AOR (95% CI)* | P* | |
|---|---|---|---|---|---|---|
| TT/TC | CC | |||||
| Age, months | ||||||
| ≤18 | 126/135 | 11/4 | 2.95 (0.92–9.49) | 0.070 | 2.95 (0.92–9.51) | 0.070 |
| >18 | 246/321 | 17/13 | 1.71 (0.81–3.58) | 0.158 | 1.71 (0.81–3.58) | 0.157 |
| Sex | ||||||
| Female | 179/217 | 12/8 | 1.82 (0.73–4.55) | 0.201 | 1.82 (0.73–4.55) | 0.201 |
| Male | 193/239 | 16/9 | 2.20 (0.95–5.09) | 0.065 | 2.19 (0.95–5.08) | 0.067 |
| Site of origin | ||||||
| Adrenal gland | 86/456 | 7/17 | 2.18 (0.88–5.42) | 0.093 | 2.17 (0.87–5.39) | 0.096 |
| Retroperitoneal | 155/456 | 11/17 | 1.91 (0.87–4.16) | 0.105 | 1.91 (0.88–4.18) | 0.104 |
| Mediastinum | 111/456 | 8/17 | 1.93 (0.81–4.59) | 0.136 | 1.93 (0.81–4.59) | 0.136 |
| Others | 16/456 | 2/17 | 3.35 (0.71–15.76) | 0.126 | 3.53 (0.74–16.73) | 0.113 |
| Clinical stage | ||||||
| I+II+4s | 164/456 | 9/17 | 1.47 (0.64–3.37) | 0.360 | 1.51 (0.66–3.46) | 0.332 |
| III+IV | 151/456 | 12/17 | 2.13 (1.00–4.57) | 0.051 | 2.12 (0.98–4.56) | 0.055 |
AOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.
Adjusted for age and sex, omitting the corresponding stratification factor.
However, no significant difference was found for the MIR938 rs2505901 T>C polymorphism and neuroblastoma risk in the stratification analyses among different age groups (in months), sex groups, site of origin groups, and clinical stage groups. The rs2505901 T>C showed a borderline significant correlation with age, sex and clinical stage. Our study revealed that the children with age ≤18 months were more likely to carry the rs2505901 CC genotype (adjusted OR = 2.95, 95% CI = 0.92–9.51, P=0.070). Compared with females, males were more likely to carry the rs2505901 CC genotype (adjusted OR = 2.19, 95% CI = 0.95–5.08, P=0.067). Moreover, carriers of the CC genotype had an increased risk of INSS clinical stage III+IV than that of carriers of the TT/TC genotype (adjusted OR = 2.12, 95% CI = 0.98–4.56, P=0.055).
Discussion
To explore the association between the MIR938 polymorphism and neuroblastoma, we undertook a case‒control study specifically focused on Chinese children. Our study showed that the MIR938 rs2505901 T>C polymorphism could predispose the Chinese population to neuroblastoma risk. In spite of the lack of statistical significance in the subsequent stratified studies, rs2505901 T>C showed a borderline difference correlation with age, sex and clinical stage.
MIR938 is located on Homo sapiens chromosome 10, GRCh38.p14 Primary Assembly. The transcription product of MIR938 is a kind of miRNA, which is a class of small (20–24 nt) noncoding RNAs that orchestrate the posttranscriptional regulation of gene expression in multicellular organisms [32].
Previous studies revealed that MIR938 plays critical roles in several reproductive disorders [25,26]. MIR938 can prevent the risk of idiopathic recurrent pregnancy loss, and its potential mechanisms to affect the female reproductive system involve the TGF-β signaling pathway [33]. Although the underlying mechanisms by which the MIR938 G>A polymorphism contribute to the development of primary ovarian insufficiency have not yet been elucidated, Cho et al. showed that MIR938 G>A polymorphism might be attributed to the regulation of POI-related target genes, mostly the gonadotropin-releasing hormone receptor [25].
On the other hand, MIR938 plays an important role in CRC and intestinal-type GC. Landeros et al. showed that MIR938 rs12416605 C>T was associated with intestinal-type GC risk in a Chilean population [23]. The underlying mechanism entails alteration of the initial nucleotide within the seed region of MIR938 while leaving the secondary structure unaffected. Another study showed that MIR938 is up-regulated in CRC tissues and cells and can promote CRC cell proliferation by inhibiting leucine-rich repeat protein phosphatase 2 [24].
Our findings indicate a significant association between the MIR938 rs2505901 T>C polymorphism and an increased risk to neuroblastoma. However, further stratified analyses did not show significant differences among different age groups, sex groups, site of origin groups, and clinical stage groups. In the stratified analysis, we found that rs2505901 T>C showed weak correlations with age ≤18 months, male sex, and clinical stage III+IV. The rs2505901 is an upstream variant located in the intron region of the MIR938 gene. MIR938 can influence the regulatory pathways of cell apoptosis and survival. The GTEx portal showed that the rs2505901 TT/CT genotypes may inhibit these regulatory pathways by lowering the expression of MIR938 compared with that in the CC genotype, and the SNP-like variants of the pre-MIR938 gene were associated with MIR938 biogenesis and stability. This may be a potential mechanism by which the MIR938 rs2505901 T>C polymorphism is associated with increased neuroblastoma risk.
The present study represents the first investigation between MIR938 rs2505901 T>C polymorphism and the risk of neuroblastoma among the Chinese pediatric population. Nevertheless, there are still some weaknesses. First, due to the limited sample size of our case‒control study among Chinese children, the statistical power of our findings might be somewhat compromised. Second, we only focused on a single polymorphism in MIR938; hence, the impact of MIR938 polymorphisms may be overshadowed by other genetic factors. Further investigation of additional potentially functional polymorphisms within MIR938 is needed. Third, polymorphisms can manifest varied genetic influences on the susceptibility to different types of cancer, owing to factors such as geographic regions and ethnic backgrounds. The lack of an observed association between the one MIR938 polymorphism and NB may be attributed to ethnic differences. Therefore, caution is advised when extrapolating the findings to other ethnic populations. Fourth, our research group was NB patients and volunteers from the Children’s Hospital of Nanjing Medical University, not healthy volunteers, even though we matched the two groups demographically. Thus, bias may exist in the results. Fifth, our research adapted the TaqMan real-time PCR method for the genotype. The gold standard should be used for secondary analysis to ensure the first method accuracy. Lacking of validation is a limitation of the study.
In summary, our present data indicated that MIR938 rs2505901 was significantly associated with NB risk. However, there was no marked difference in the stratification analysis. We still found a weak association between age, sex and clinical stage and NB susceptibility. Well-designed studies in large samples and diverse ethnic groups are needed to confirm our findings.
Supplementary Material
Abbreviations
- CI
confidence interval
- CRC
colorectal cancer
- GWAS
genome-wide association study
- HWE
Hardy–Weinberg equilibrium
- INSS
International Neuroblastoma Staging System
- intestinal-type GC
intestinal-type gastric cancer
- miRNA
microRNA
- NB
neuroblastoma
- OR
odds ratio
- SNP
single-nucleotide polymorphism
Contributor Information
Jing He, Email: hejing@gwcmc.org.
Wenhan Yang, Email: wenhan-yang@gdpu.edu.cn.
Data Availability
All the data are available upon request from the corresponding authors.
Competing Interests
The authors declare that there are no competing interests associated with the manuscript.
Funding
This study was supported by grants from the Guangdong Basic and Applied Basic Research Foundation [grant number 2021A1515111116]; the Postdoctoral Science Foundation of China [grant number 2021M691649]; and the Postdoctoral Science Foundation of Jiangsu Province [grant number 2021K524C].
CRediT Author Contribution
Susu Jiang: Investigation, Writing—original draft. Xiuhong Sun: Investigation, Writing—original draft, Writing—review & editing. Xinxin Zhang: Funding acquisition, Investigation, Writing—original draft. Chunlei Zhou: Resources, Funding acquisition, Investigation, Writing—review & editing. Haiyan Wu: Conceptualization, Resources, Investigation, Writing—review & editing. Jing He: Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Writing—original draft, Writing—review & editing. Wenhan Yang: Conceptualization, Supervision, Investigation, Writing—review & editing.
References
- 1.Ponzoni M., Bachetti T., Corrias M.V., Brignole C., Pastorino F., Calarco E.et al. (2022) Recent advances in the developmental origin of neuroblastoma: an overview. J. Exp. Clin. Cancer Res. 41, 92 10.1186/s13046-022-02281-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Maris J.M. (2010) Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202–2211 10.1056/NEJMra0804577 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Hero B., Simon T., Spitz R., Ernestus K., Gnekow A.K., Scheel-Walter H.G.et al. (2008) Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J. Clin. Oncol. 26, 1504–1510 10.1200/JCO.2007.12.3349 [DOI] [PubMed] [Google Scholar]
- 4.Maris J.M., Hogarty M.D., Bagatell R. and Cohn S.L. (2007) Neuroblastoma. Lancet 369, 2106–2120 10.1016/S0140-6736(07)60983-0 [DOI] [PubMed] [Google Scholar]
- 5.Matthay K.K., Maris J.M., Schleiermacher G., Nakagawara A., Mackall C.L., Diller L.et al. (2016) Neuroblastoma. Nat. Rev. Dis. Primers 2, 16078 10.1038/nrdp.2016.78 [DOI] [PubMed] [Google Scholar]
- 6.Bluhm E.C., Daniels J., Pollock B.H., Olshan A.F. and Children's Oncology G (2006) Maternal use of recreational drugs and neuroblastoma in offspring: a report from the Children's Oncology Group (United States). Cancer Causes Control. 17, 663–669 10.1007/s10552-005-0580-3 [DOI] [PubMed] [Google Scholar]
- 7.Khan A., Feulefack J. and Sergi C.M. (2022) Pre-conceptional and prenatal exposure to pesticides and pediatric neuroblastoma. A meta-analysis of nine studies. Environ. Toxicol. Pharmacol. 90, 103790 10.1016/j.etap.2021.103790 [DOI] [PubMed] [Google Scholar]
- 8.McCall E.E., Olshan A.F. and Daniels J.L. (2005) Maternal hair dye use and risk of neuroblastoma in offspring. Cancer Causes Control. 16, 743–748 10.1007/s10552-005-1229-y [DOI] [PubMed] [Google Scholar]
- 9.Longo L., Tonini G.P., Ceccherini I. and Perri P. (2005) Oligogenic inheritance in neuroblastoma. Cancer Lett. 228, 65–69 10.1016/j.canlet.2004.12.052 [DOI] [PubMed] [Google Scholar]
- 10.Ambros P.F., Ambros I.M., Brodeur G.M., Haber M., Khan J., Nakagawara A.et al. (2009) International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br. J. Cancer 100, 1471–1482 10.1038/sj.bjc.6605014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Westermark U.K., Wilhelm M., Frenzel A. and Henriksson M.A. (2011) The MYCN oncogene and differentiation in neuroblastoma. Semin. Cancer Biol. 21, 256–266 10.1016/j.semcancer.2011.08.001 [DOI] [PubMed] [Google Scholar]
- 12.Zeid R., Lawlor M.A., Poon E., Reyes J.M., Fulciniti M., Lopez M.A.et al. (2018) Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat. Genet. 50, 515–523 10.1038/s41588-018-0044-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M.et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971–974 10.1038/nature07399 [DOI] [PubMed] [Google Scholar]
- 14.George R.E., Sanda T., Hanna M., Frohling S., Luther W. II, Zhang J.et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975–978 10.1038/nature07397 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V.et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967–970 10.1038/nature07398 [DOI] [PubMed] [Google Scholar]
- 16.Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F.et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930–935 10.1038/nature07261 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Bourdeaut F., Trochet D., Janoueix-Lerosey I., Ribeiro A., Deville A., Coz C.et al. (2005) Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Lett. 228, 51–58 10.1016/j.canlet.2005.01.055 [DOI] [PubMed] [Google Scholar]
- 18.Trochet D., Bourdeaut F., Janoueix-Lerosey I., Deville A., de Pontual L., Schleiermacher G.et al. (2004) Germline mutations of the paired–like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 74, 761–764 10.1086/383253 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Pugh T.J., Morozova O., Attiyeh E.F., Asgharzadeh S., Wei J.S., Auclair D.et al. (2013) The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279–284 10.1038/ng.2529 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Peifer M., Hertwig F., Roels F., Dreidax D., Gartlgruber M., Menon R.et al. (2015) Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526, 700–704 10.1038/nature14980 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Rupaimoole R. and Slack F.J. (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16, 203–222 10.1038/nrd.2016.246 [DOI] [PubMed] [Google Scholar]
- 22.Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D.et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435, 834–838 10.1038/nature03702 [DOI] [PubMed] [Google Scholar]
- 23.Landeros N., Corvalan A.H., Musleh M., Quinones L.A., Varela N.M. and Gonzalez-Hormazabal P. (2021) Novel risk associations between microRNA polymorphisms and gastric cancer in a chilean population. Int. J. Mol. Sci. 23, 467 10.3390/ijms23010467 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Li C.F., Li Y.C., Jin J.P., Yan Z.K. and Li D.D. (2017) miR-938 promotes colorectal cancer cell proliferation via targeting tumor suppressor PHLPP2. Eur. J. Pharmacol. 807, 168–173 10.1016/j.ejphar.2017.04.023 [DOI] [PubMed] [Google Scholar]
- 25.Cho S.H., Ahn E.H., An H.J., Kim J.H., Ko J.J., Kim Y.R.et al. (2017) Association of miR-938G>A polymorphisms with primary ovarian insufficiency (POI)-related gene expression. Int. J. Mol. Sci. 18, 1255 10.3390/ijms18061255 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Cho S.H., Kim J.H., An H.J., Kim Y.R., Ahn E.H., Lee J.R.et al. (2021) Genetic polymorphisms in miR-604A>G, miR-938G>A, miR-1302-3C>T and the risk of idiopathic recurrent pregnancy loss. Int. J. Mol. Sci. 22, 6127 10.3390/ijms22116127 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Stadler Z.K., Thom P., Robson M.E., Weitzel J.N., Kauff N.D., Hurley K.E.et al. (2010) Genome-wide association studies of cancer. J. Clin. Oncol. 28, 4255–4267 10.1200/JCO.2009.25.7816 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Brodeur G.M., Pritchard J., Berthold F., Carlsen N.L., Castel V., Castelberry R.P.et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11, 1466–1477 10.1200/JCO.1993.11.8.1466 [DOI] [PubMed] [Google Scholar]
- 29.Lin L., Deng C., Zhou C., Zhang X., Zhu J., Liu J.et al. (2023) NSUN2 gene rs13181449 C>T polymorphism reduces neuroblastoma risk. Gene 854, 147120 10.1016/j.gene.2022.147120 [DOI] [PubMed] [Google Scholar]
- 30.Zhuo Z.J., Zhang R., Zhang J., Zhu J., Yang T., Zou Y.et al. (2018) Associations between lncRNA MEG3 polymorphisms and neuroblastoma risk in Chinese children. Aging (Albany NY) 10, 481–491 10.18632/aging.101406 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Zhuo Z.J., Liu W., Zhang J., Zhu J., Zhang R., Tang J.et al. (2018) Functional Polymorphisms at ERCC1/XPF Genes Confer Neuroblastoma Risk in Chinese Children. EBioMedicine 30, 113–119 10.1016/j.ebiom.2018.03.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Bartel D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 10.1016/S0092-8674(04)00045-5 [DOI] [PubMed] [Google Scholar]
- 33.Butz H., Liko I., Czirjak S., Igaz P., Korbonits M., Racz K.et al. (2011) MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary 14, 112–124 10.1007/s11102-010-0268-x [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All the data are available upon request from the corresponding authors.
